Skip to Content

274 Results Found

  • Article
  • Open Access
2,059 Views
16 Pages

BRAF Inhibition and UVB Light Synergistically Promote Mus musculus Papillomavirus 1-Induced Skin Tumorigenesis

  • Sonja Dorfer,
  • Julia Maria Ressler,
  • Katharina Riebenbauer,
  • Stefanie Kancz and ,
  • Kim Purkhauser,
  • Victoria Bachmayr,
  • Christophe Cataisson,
  • Reinhard Kirnbauer,
  • Peter Petzelbauer and
  • Alessandra Handisurya
  • + 8 authors+ 3 authors

11 September 2024

The development of keratinocytic skin tumors, presumably attributable to paradoxical activation of the MAPK pathway, represents a relevant side effect of targeted therapies with BRAF inhibitors (BRAFis). The role of cutaneous papillomavirus infection...

(This article belongs to the Special Issue Advances in Skin Cancer: Diagnosis, Treatment and Prognosis)
  • Communication
  • Open Access
3,497 Views
11 Pages

Resistance to MAPK Pathway Inhibition in BRAF-V600E Mutant Colorectal Cancer Can Be Overcome with Insulin Receptor/Insulin-like Growth Factor-1 Receptor Inhibitors

  • Layla El Bouazzaoui,
  • Daniëlle A. E. Raats,
  • André Verheem,
  • Inne H. M. Borel Rinkes and ,
  • Hugo J. G. Snippert,
  • Madelon M. Maurice and
  • Onno Kranenburg
  • + 2 authors+ 0 author

The current treatment for refractory BRAF-V600E mutant metastatic colorectal cancer (mCRC) involves combined inhibition of BRAF and the epidermal growth factor receptor (EGFR). However, tumour responses are often short-lived due to a rebound in mitog...

  • Article
  • Open Access
16 Citations
5,826 Views
16 Pages

21 February 2021

Whereas the prevalence of several cancer types is decreasing, skin malignancies are growing more common every year. Malignant melanoma is the most aggressive form of skin cancer with high metastatic capacity. In most cases, malignant melanoma shows a...

(This article belongs to the Special Issue Antioxidants, Phytonutrients and Cancer Risk)
  • Review
  • Open Access
33 Citations
8,541 Views
23 Pages

13 July 2021

Several BRAF-driven cancers, including advanced BRAFV600E/K-driven melanoma, non-small-cell lung carcinoma, and thyroid cancer, are currently treated using first-line inhibitor combinations of BRAFV600E plus MEK1/2. However, despite the success of th...

(This article belongs to the Collection Drug Resistance and Novel Therapies in Cancers)
  • Review
  • Open Access
19 Citations
6,394 Views
17 Pages

2 October 2023

BRAF is one of the most frequently mutated oncogenes, with an overall frequency of about 50%. Targeting BRAF and its effector mitogen-activated protein kinase kinase 1/2 (MEK1/2) is now a key therapeutic strategy for BRAF-mutant tumors, and therapies...

(This article belongs to the Special Issue MAPK Signaling Cascades in Human Health and Diseases)
  • Article
  • Open Access
26 Citations
4,156 Views
16 Pages

Dual Inhibition of BRAF-MAPK and STAT3 Signaling Pathways in Resveratrol-Suppressed Anaplastic Thyroid Cancer Cells with BRAF Mutations

  • Meng-Di Lu,
  • Hong Li,
  • Jun-Hua Nie,
  • Sheng Li and ,
  • Hai-Shan Ye,
  • Ting-Ting Li,
  • Mo-Li Wu and
  • Jia Liu
  • + 3 authors+ 0 author

19 November 2022

Anaplastic thyroid cancer is an extremely lethal malignancy without reliable treatment. BRAFV600E point mutation is common in ATCs, which leads to MAPK signaling activation and is regarded as a therapeutic target. Resveratrol inhibits ATC cell growth...

(This article belongs to the Special Issue New Insights in Natural Bioactive Compounds)
  • Article
  • Open Access
8 Citations
2,036 Views
15 Pages

Combinatorial ERK Inhibition Enhances MAPK Pathway Suppression in BRAF-Mutant Melanoma

  • Corinna Kosnopfel,
  • Tobias Sinnberg,
  • Shrunal Mane,
  • Michelle Dongo and ,
  • Claus Garbe and
  • Heike Niessner
  • + 1 author+ 0 author

8 October 2025

Small molecule inhibitors targeting BRAF mutations at V600 and downstream MEK represent a significant advancement in treating BRAF-mutant melanoma. However, resistance mechanisms, often involving reactivation of the MAPK pathway via ERK1/2, limit the...

(This article belongs to the Special Issue Novel Therapeutic Targets in Cancers: 3rd Edition)
  • Article
  • Open Access
14 Citations
3,743 Views
17 Pages

Fibroblasts Influence Metastatic Melanoma Cell Sensitivity to Combined BRAF and MEK Inhibition

  • Delphine Morales,
  • Pascale Vigneron,
  • Ines Ferreira,
  • Warda Hamitou and ,
  • Mikael Magnano,
  • Laxsika Mahenthiran,
  • Catherine Lok and
  • Muriel Vayssade
  • + 3 authors+ 0 author

23 September 2021

The sensitivity of melanoma cells to targeted therapy compounds depends on the tumor microenvironment. Three-dimensional (3D) in vitro coculture systems better reflect the native structural architecture of tissues and are ideal for investigating cell...

(This article belongs to the Special Issue Study on the Complex Melanoma)
  • Article
  • Open Access
9 Citations
4,511 Views
14 Pages

Combined HP 13C Pyruvate and 13C-Glucose Fluxomic as a Potential Marker of Response to Targeted Therapies in YUMM1.7 Melanoma Xenografts

  • Chantale Farah,
  • Marie-Aline Neveu,
  • Caner Yelek,
  • Caroline Bouzin and ,
  • Bernard Gallez,
  • Jean-François Baurain,
  • Lionel Mignion and
  • Bénédicte F. Jordan
  • + 3 authors+ 0 author

A vast majority of BRAF V600E mutated melanoma patients will develop resistance to combined BRAF/MEK inhibition after initial clinical response. Resistance to targeted therapy is described to be accompanied by specific metabolic changes in melanoma....

(This article belongs to the Special Issue Advanced Research in Molecular Imaging of Immunity and Inflammation)
  • Case Report
  • Open Access

Tattoo-Limited Granulomatous Reactions During BRAF/MEK Inhibition in Metastatic Melanoma: Further Clinical Experience from Two Additional Cases

  • Vincenzo Coppolelli,
  • Giuseppe Rizzuto,
  • Alberto Taliano,
  • Luca Guarino and ,
  • Lako Kostika,
  • Claudio Di Cristofano,
  • Concetta Potenza,
  • Steven Paul Nisticò,
  • Luca Filippi and
  • Ilaria Proietti
  • + 5 authors+ 0 author

16 November 2026

Background/Objectives: Tattoo-associated inflammatory reactions during BRAF/MEK inhibitor therapy are uncommon and remain poorly characterized. Building on the case previously reported by Baratta et al., we describe two additional patients with melan...

(This article belongs to the Special Issue Cutaneous Oncology: Advances in Melanoma, Basal Cell Carcinoma and Other Skin Cancers)
  • Article
  • Open Access
31 Citations
4,082 Views
20 Pages

Identification of Benzothiazoles Bearing 1,3,4-Thiadiazole as Antiproliferative Hybrids Targeting VEGFR-2 and BRAF Kinase: Design, Synthesis, BIO Evaluation and In Silico Study

  • Wafaa A. Ewes,
  • Samar S. Tawfik,
  • Aya M. Almatary,
  • Mashooq Ahmad Bhat and ,
  • Hamed W. El-Shafey,
  • Ahmed A. B. Mohamed,
  • Abdullah Haikal,
  • Mohammed A. El-Magd,
  • Abdullah A. Elgazar and
  • Abdelrahman Hamdi
  • + 6 authors+ 1 author

Cancer remains a leading cause of death worldwide, often resulting from uncontrolled growth in various organs. Protein kinase inhibitors represent an important class of targeted cancer therapies. Recently, the kinases BRAF and VEGFR-2 have shown syne...

(This article belongs to the Special Issue Synthesis of Bioactive Compounds: Volume II)
  • Review
  • Open Access
102 Citations
15,665 Views
13 Pages

23 September 2015

Colorectal cancer (CRC) is a heterogeneous disease with multiple underlying causative genetic mutations. Genetic mutations in the phosphatidylinositol-3 kinase (PI3K) and the mitogen activated protein kinase (MAPK) pathways are frequently implicated...

(This article belongs to the Special Issue Molecular Classification of Human Cancer: Diagnosis and Treatment)
  • Article
  • Open Access
11 Citations
4,458 Views
18 Pages

Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations

  • Dominika Rittler,
  • Eszter Molnár,
  • Marcell Baranyi,
  • Tamás Garay and ,
  • Luca Hegedűs,
  • Clemens Aigner,
  • József Tóvári,
  • József Tímár and
  • Balázs Hegedűs
  • + 4 authors+ 0 author

16 October 2020

The RAS/RAF and PI3K/Akt pathways play a key regulatory role in cancer and are often hit by oncogenic mutations. Despite molecular targeting, the long-term success of monotherapy is often hampered by de novo or acquired resistance. In the case of con...

(This article belongs to the Special Issue Targeting MAPK in Cancer)
  • Article
  • Open Access
23 Citations
5,985 Views
18 Pages

The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma

  • Mohammad Krayem,
  • Malak Sabbah,
  • Ahmad Najem,
  • An Wouters and ,
  • Filip Lardon,
  • Stephane Simon,
  • François Sales,
  • Fabrice Journe,
  • Ahmad Awada and
  • Dirk Van Gestel
  • + 6 authors+ 1 author

1 August 2019

Radiotherapy (RT) in patients with melanoma historically showed suboptimal results, because the disease is often radioresistant due to various mechanisms such as scavenging free radicals by thiols, pigmentary machinery, or enhanced DNA repair. Howeve...

(This article belongs to the Collection Drug Resistance and Novel Therapies in Cancers)
  • Article
  • Open Access
12 Citations
5,027 Views
24 Pages

BRAFV600E mutations are found in approximately 10% of colorectal cancer patients and are associated with worse prognosis and poor outcomes with systemic therapies. The aim of this study was to identify novel druggable features of BRAFV600E-mutated co...

(This article belongs to the Special Issue Cancer Chemoresistance: Novel Mechanistic Insights and Emerging Therapeutic Strategies)
  • Review
  • Open Access
7 Citations
3,375 Views
34 Pages

7 November 2025

Melanoma is an aggressive form of skin cancer marked by unique genetic alterations that promote tumor growth and resistance to therapy. Advances in targeted therapy have markedly improved clinical outcomes by selectively inhibiting key oncogenic path...

(This article belongs to the Section Dermatology)
  • Article
  • Open Access
15 Citations
5,308 Views
13 Pages

Dual SMO/BRAF Inhibition by Flavonolignans from Silybum marianum

  • Antonia Diukendjieva,
  • Maya M. Zaharieva,
  • Mattia Mori,
  • Petko Alov and ,
  • Ivanka Tsakovska,
  • Tania Pencheva,
  • Hristo Najdenski,
  • Vladimír Křen,
  • Chiara Felici and
  • Ilza Pajeva
  • + 9 authors+ 4 authors

Silymarin is the standardized extract from the fruits of Silybum marianum (L.) Gaertn., a well-known hepatoprotectant and antioxidant. Recently, bioactive compounds of silymarin, i.e., silybins and their 2,3-dehydro derivatives, have been shown to ex...

(This article belongs to the Special Issue Antioxidant and Cytoprotective Activity)
  • Communication
  • Open Access
9 Citations
4,215 Views
7 Pages

Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants

  • Francesco Spagnolo,
  • Bruna Dalmasso,
  • Enrica Tanda,
  • Miriam Potrony and ,
  • Susana Puig,
  • Remco van Doorn,
  • Ellen Kapiteijn,
  • Paola Queirolo,
  • Hildur Helgadottir and
  • Paola Ghiorzo
  • + 5 authors+ 0 author

18 May 2021

Inherited pathogenic variants (PVs) in the CDKN2A tumor suppressor gene are among the strongest risk factors for cutaneous melanoma. Dysregulation of the p16/RB1 pathway may intrinsically limit the activity of MAPK-directed therapy due to the interpl...

(This article belongs to the Special Issue Systemic Therapies in Melanoma)
  • Article
  • Open Access
8 Citations
4,310 Views
21 Pages

Therapeutic Potential of Glutaminase Inhibition Targeting Metabolic Adaptations in Resistant Melanomas to Targeted Therapy

  • Laura Soumoy,
  • Aline Genbauffe,
  • Dorianne Sant’Angelo,
  • Maude Everaert and ,
  • Léa Mukeba-Harchies,
  • Jean-Emmanuel Sarry,
  • Anne-Emilie Declèves and
  • Fabrice Journe
  • + 3 authors+ 0 author

25 August 2025

Targeted therapy with BRAFi has significantly improved outcomes for patients with BRAF-mutated metastatic melanoma. However, resistance mechanisms, particularly metabolic adaptations, such as increased glutaminolysis, present substantial clinical cha...

(This article belongs to the Special Issue Molecular Mechanisms and Therapies for Melanoma)
  • Article
  • Open Access
9 Citations
2,012 Views
17 Pages

Synergistic ROS Reduction Through the Co-Inhibition of BRAF and p38 MAPK Ameliorates Senescence

  • Myeong Uk Kuk,
  • Duyeol Kim,
  • Yun Haeng Lee,
  • Jee Hee Yoon and ,
  • Ji Ho Park,
  • Yoo Jin Lee,
  • Byeong Hyeon So,
  • Minseon Kim,
  • Hyung Wook Kwon and
  • Joon Tae Park
  • + 6 authors+ 1 author

28 November 2024

Reactive oxygen species (ROS)-mediated damage to macromolecules and cellular organelles is one of the major causes of senescence. Therapeutic strategies that lower ROS levels have been proposed as important treatments for senescence, but effective me...

(This article belongs to the Special Issue Mitochondrial Oxidative Stress in Aging and Disease—2nd Edition)
  • Article
  • Open Access
13 Citations
5,159 Views
18 Pages

BRAF/EZH2 Signaling Represses miR-129-5p Inhibition of SOX4 Thereby Modulating BRAFi Resistance in Melanoma

  • Kathleen Gebhardt,
  • Bayram Edemir,
  • Elisabeth Groß,
  • Linda Nemetschke and ,
  • Stefanie Kewitz-Hempel,
  • Rose K. C. Moritz,
  • Cord Sunderkötter and
  • Dennis Gerloff
  • + 3 authors+ 0 author

15 May 2021

Many melanomas are associated with activating BRAF mutation. Targeted therapies by inhibitors of BRAF and MEK (BRAFi, MEKi) show marked antitumor response, but become limited by drug resistance. The mechanisms for this are not fully revealed, but inc...

(This article belongs to the Section Molecular Cancer Biology)
  • Review
  • Open Access
33 Citations
5,294 Views
16 Pages

Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review

  • Austin Greco,
  • Danish Safi,
  • Umang Swami,
  • Tim Ginader and ,
  • Mohammed Milhem and
  • Yousef Zakharia
  • + 1 author+ 0 author

5 December 2019

We reviewed the literature to assess the efficacy and risk of constitutional, cardiac, gastrointestinal, and dermatological toxicities of combined BRAF plus MEK inhibitors versus BRAF inhibitors alone in patients with metastatic melanoma with BRAF mu...

(This article belongs to the Special Issue Targeted Therapies for Melanoma)
  • Communication
  • Open Access
4 Citations
3,546 Views
21 Pages

Secretome Screening of BRAFV600E-Mutated Colon Cancer Cells Resistant to Vemurafenib

  • Iris Car,
  • Antje Dittmann,
  • Marko Klobučar,
  • Petra Grbčić and ,
  • Sandra Kraljević Pavelić and
  • Mirela Sedić
  • + 1 author+ 0 author

17 April 2023

Patients with metastatic colorectal cancer (mCRC) carrying BRAFV600E mutation have worse response to chemotherapy and poor prognosis. The BRAFV600E inhibitor vemurafenib has shown modest efficacy as monotherapy in BRAF-mutated mCRC due to the develop...

(This article belongs to the Section Cancer Biology)
  • Case Report
  • Open Access
1 Citations
2,566 Views
10 Pages

Impact of BRAF and MEK Inhibitors on Gingival Hyperplasia in Melanoma Patients—A Case Report

  • Tanja Veljovic,
  • Milanko Djuric,
  • Ivana Gusic,
  • Nada Vuckovic and ,
  • Bojana Ramic and
  • Jelena Mirnic
  • + 1 author+ 0 author

26 December 2024

Background: Although BRAF inhibitors, such as vemurafenib, produce a marked response in patients with advanced melanoma with a BRAF V600 mutation, they eventually develop resistance to this treatment. To address this issue, vemurafenib is increasingl...

(This article belongs to the Section Oncology)
  • Review
  • Open Access
7 Citations
6,734 Views
23 Pages

Pediatric gliomas encompass the most common brain tumor in children and are subdivided into pediatric low-grade gliomas (pLGGs) and pediatric high-grade gliomas (pHGGs). The era of molecular diagnosis has shifted the treatment paradigms and managemen...

(This article belongs to the Special Issue Clinical Outcomes and New Treatments in Pediatric Brain Tumors)
  • Article
  • Open Access
6 Citations
6,009 Views
14 Pages

Novel Anti-Melanoma Compounds Are Efficacious in A375 Cell Line Xenograft Melanoma Model in Nude Mice

  • Sadeeshkumar Velayutham,
  • Ryan Seerattan,
  • Maab Sultan,
  • Trisha Seal and ,
  • Samaya Danthurthy,
  • Baskaran Chinnappan,
  • Jessica Landi,
  • Kaitlyn Pearl,
  • Aveta Singh and
  • Dmitriy Minond
  • + 8 authors+ 3 authors

22 August 2023

Despite the successes of immunotherapy, melanoma remains one of the deadliest cancers, therefore, the need for innovation remains high. We previously reported anti-melanoma compounds that work by downregulating spliceosomal proteins hnRNPH1 and H2. I...

(This article belongs to the Special Issue Advances in Melanoma Targeted Therapy)
  • Review
  • Open Access
11 Citations
5,832 Views
26 Pages

26 January 2026

Melanoma was once considered ‘incurable’; however, drug therapy for the condition has dramatically transformed with the advent of immune checkpoint inhibitors and molecular targeted therapies. In this review, we summarize the published li...

(This article belongs to the Special Issue New Strategies for the Treatment of Melanoma and Non-Melanoma Skin Cancer)
  • Review
  • Open Access
1,035 Views
23 Pages

Current Molecular-Targeted Therapies in Melanoma and Their Mechanism of Resistance

  • Rose Bahari,
  • Molly Nguyen,
  • Nayyab Sohail,
  • Stephanie Lopez and ,
  • Subaranjana Saravanaguru Vasanthi,
  • Jeeya Amin,
  • Dhruv Ramaswami,
  • Georgia Kapetaneas,
  • Riya Karne and
  • Neelu Puri
  • + 8 authors+ 3 authors

17 July 2026

Melanoma is an aggressive skin cancer that has the potential to metastasize to the lymph nodes, lungs, liver, and brain. Therefore, the prevention and treatment of this condition are essential for achieving lower incidence rates and improving patient...

(This article belongs to the Section Molecular Cancer Biology)
  • Article
  • Open Access
26 Citations
3,520 Views
12 Pages

STM2457 Inhibits the Invasion and Metastasis of Pancreatic Cancer by Down-Regulating BRAF-Activated Noncoding RNA N6-Methyladenosine Modification

  • Shaolong Hao,
  • Haitao Sun,
  • Hao Sun,
  • Bo Zhang and ,
  • Kailun Ji,
  • Peng Liu,
  • Fang Nie and
  • Wei Han
  • + 3 authors+ 0 author

3 November 2023

Pancreatic cancer is a malignant tumor of the digestive system that is highly malignant, difficult to treat, and confers a poor prognosis for patients. BRAF-activated noncoding RNA (BANCR) has been proven to play an important role in the invasion and...

(This article belongs to the Special Issue Adhesion, Metastasis and Inhibition of Cancer Cells)
  • Article
  • Open Access
10 Citations
4,398 Views
17 Pages

Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma

  • Anne Uebel,
  • Stefanie Kewitz-Hempel,
  • Edith Willscher,
  • Kathleen Gebhardt and ,
  • Cord Sunderkötter and
  • Dennis Gerloff
  • + 1 author+ 0 author

19 January 2023

Activating BRAF mutations occurs in 50–60% of malignant melanomas. Although initially treatable, the development of resistance to BRAF-targeted therapies (BRAFi) is a major challenge and limits their efficacy. We have previously shown that the...

(This article belongs to the Special Issue Molecular Research and New Therapy in Melanoma and Other Skin Cancers)
  • Article
  • Open Access
19 Citations
4,927 Views
23 Pages

Vemurafenib and Dabrafenib Downregulates RIPK4 Level

  • Ewelina Madej,
  • Anna A. Brożyna,
  • Agnieszka Adamczyk,
  • Norbert Wronski and ,
  • Agnieszka Harazin-Lechowska,
  • Anna Muzyk,
  • Krzysztof Makuch,
  • Michal Markiewicz,
  • Janusz Rys and
  • Agnieszka Wolnicka-Glubisz
  • + 5 authors+ 0 author

1 February 2023

Vemurafenib and dabrafenib are BRAF kinase inhibitors (BRAFi) used for the treatment of patients with melanoma carrying the V600E BRAF mutation. However, melanoma cells develop resistance to both drugs when used as monotherapy. Therefore, mechanisms...

(This article belongs to the Special Issue Molecular Mechanisms of Anti-Cancer Drugs Action)
  • Article
  • Open Access
29 Citations
3,647 Views
15 Pages

PD-L1 Is an Independent Prognostic Marker in Middle Eastern PTC and Its Expression Is Upregulated by BRAFV600E Mutation

  • Abdul K. Siraj,
  • Sandeep Kumar Parvathareddy,
  • Poyil Pratheeshkumar,
  • Sasidharan Padmaja Divya and ,
  • Saif S. Al-Sobhi,
  • Fouad Al-Dayel and
  • Khawla S. Al-Kuraya
  • + 2 authors+ 0 author

1 February 2021

PD-L1 inhibition is a promising therapeutic target whose efficacy has been demonstrated in several cancers. Immunohistochemistry was performed to assess PD-L1 protein expression in PTC. We further conducted in vitro analysis to investigate the role o...

(This article belongs to the Collection Mechanism of Immunotherapy in Cancers)
  • Article
  • Open Access
12 Citations
5,529 Views
15 Pages

12 December 2023

The BRAF V600E mutation is frequently found in cancer. It activates the MAPK pathway and promotes cancer cell proliferation, making BRAF an excellent target for anti-cancer therapy. While BRAF-targeted therapy is highly effective for melanoma, it is...

(This article belongs to the Section Cancer Pathophysiology)
  • Article
  • Open Access
10 Citations
4,228 Views
16 Pages

SB202190 Predicts BRAF-Activating Mutations in Primary Colorectal Cancer Organoids via Erk1-2 Modulation

  • Delfina Costa,
  • Roberta Venè,
  • Simona Coco,
  • Luca Longo and ,
  • Francesca Tosetti,
  • Stefano Scabini,
  • Luca Mastracci,
  • Federica Grillo,
  • Alessandro Poggi and
  • Roberto Benelli
  • + 5 authors+ 0 author

20 February 2023

The p38 inhibitor SB202190 is a necessary component of the medium used for normal colorectal mucosa cultures. Sato et al. suggested that the primary activity of SB202190 may be EGFR signaling stabilization, causing an increased phosphorylation of Erk...

  • Review
  • Open Access
170 Citations
10,316 Views
13 Pages

BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions

  • Ilaria Proietti,
  • Nevena Skroza,
  • Simone Michelini,
  • Alessandra Mambrin and ,
  • Veronica Balduzzi,
  • Nicoletta Bernardini,
  • Anna Marchesiello,
  • Ersilia Tolino,
  • Salvatore Volpe and
  • Concetta Potenza
  • + 9 authors+ 4 authors

7 July 2020

The BRAF inhibitors vemurafenib, dabrafenib and encorafenib are used in the treatment of patients with BRAF-mutant melanoma. They selectively target BRAF kinase and thus interfere with the mitogen-activated protein kinase (MAPK) signalling pathway th...

(This article belongs to the Special Issue Advances and Novel Treatment Options in Metastatic Melanoma)
  • Article
  • Open Access
16 Citations
6,742 Views
15 Pages

Establishment of Canine Transitional Cell Carcinoma Cell Lines Harboring BRAF V595E Mutation as a Therapeutic Target

  • Hyojik Jung,
  • Kieun Bae,
  • Ja Young Lee,
  • Jung-Hyun Kim and ,
  • Hyun-Jung Han,
  • Hun-Young Yoon and
  • Kyong-Ah Yoon
  • + 2 authors+ 0 author

25 August 2021

Transitional cell carcinoma (TCC) is the most common malignant tumor of the canine urinary tract and tends to have a poor prognosis due to its invasive potential. Recent studies have reported that up to 80% of canine urothelial carcinoma has the BRAF...

(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
  • Article
  • Open Access
18 Citations
5,430 Views
15 Pages

Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis

  • Melissa M. De Meza,
  • Willeke A. M. Blokx,
  • Johannes J. Bonenkamp,
  • Christian U. Blank and ,
  • Maureen J. B. Aarts,
  • Franchette W. P. J. van den Berkmortel,
  • Marye J. Boers-Sonderen,
  • Jan Willem B. De Groot,
  • John B. A. G. Haanen and
  • Michel W. J. M. Wouters
  • + 15 authors+ 10 authors

7 January 2023

Adjuvant BRAF/MEK- and anti-PD-1 inhibition have significantly improved recurrence-free survival (RFS) compared to placebo in resected stage III BRAF-mutant melanoma. However, data beyond the clinical trial setting are limited. This study describes t...

(This article belongs to the Special Issue Immunotherapy in Melanoma: Recent Advances and Future Directions)
  • Article
  • Open Access
62 Citations
13,032 Views
13 Pages

BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale

  • Jillian Wilhelmina Paulina Bracht,
  • Niki Karachaliou,
  • Trever Bivona,
  • Richard B. Lanman and ,
  • Iris Faull,
  • Rebecca J. Nagy,
  • Ana Drozdowskyj,
  • Jordi Berenguer,
  • Manuel Fernandez-Bruno and
  • Rafael Rosell
  • + 6 authors+ 1 author

17 September 2019

BRAF V600 mutations have been found in 1–2% of non-small-cell lung cancer (NSCLC) patients, with Food and Drug Administration (FDA) approved treatment of dabrafenib plus trametinib and progression free survival (PFS) of 10.9 months. However, 50...

(This article belongs to the Special Issue Oncogenic Forms of BRAF as Cancer Driver Genes)
  • Article
  • Open Access
28 Citations
5,377 Views
18 Pages

CDK4/6 Inhibition Reprograms Mitochondrial Metabolism in BRAFV600 Melanoma via a p53 Dependent Pathway

  • Nancy T. Santiappillai,
  • Shatha Abuhammad,
  • Alison Slater,
  • Laura Kirby and ,
  • Grant A. McArthur,
  • Karen E. Sheppard and
  • Lorey K. Smith
  • + 2 authors+ 0 author

29 January 2021

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are being tested in numerous clinical trials and are currently employed successfully in the clinic for the treatment of breast cancers. Understanding their mechanism of action and interaction with o...

(This article belongs to the Special Issue Systemic Therapies in Melanoma)
  • Article
  • Open Access
19 Citations
4,687 Views
23 Pages

Targeting of MAP kinase pathways by BRAF inhibitors has evolved as a key therapy for BRAF-mutated melanoma. However, it cannot be applied for BRAF-WT melanoma, and also, in BRAF-mutated melanoma, tumor relapse often follows after an initial phase of...

(This article belongs to the Special Issue Advances in Melanoma Immunotherapy and Molecular Mechanisms of Drug Resistance)
  • Abstract
  • Open Access
3 Citations
2,899 Views
1 Page

Therapeutic Potential of Black Pepper Compound for BRaf Resistant Melanoma

  • Neel M. Fofaria,
  • Sharavan Ramachandran and
  • Sanjay K. Srivastava

17 November 2017

Malignant melanoma is significant problem for Caucasian population in the western countries. Mutations in BRAF gene in 60% of patients is responsible for developing resistance to BRAF inhibitors. Our results delineated the mechanism of resistance and...

(This article belongs to the Proceedings of Proceedings of the 2nd International Conference on Natural Products for Cancer Prevention and Therapy)
  • Article
  • Open Access
11 Citations
5,651 Views
34 Pages

Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAFV600E Protein

  • Elisabetta Marini,
  • Marco Marino,
  • Giulia Gionfriddo,
  • Federica Maione and ,
  • Marta Pandini,
  • Daniele Oddo,
  • Marta Giorgis,
  • Barbara Rolando,
  • Federica Blua and
  • Massimo Bertinaria
  • + 11 authors+ 6 authors

3 December 2022

BRAF is a serine/threonine kinase frequently mutated in human cancers. BRAFV600E mutated protein is targeted through the use of kinase inhibitors which are approved for the treatment of melanoma; however, their long-term efficacy is hampered by resis...

(This article belongs to the Special Issue Exclusive Papers from the Editorial Board Members (EBMs) of the Section “Medicinal Chemistry” of Molecules)
  • Article
  • Open Access
15 Citations
3,884 Views
15 Pages

RICTOR Affects Melanoma Tumorigenesis and Its Resistance to Targeted Therapy

  • Ahlem Jebali,
  • Maxime Battistella,
  • Céleste Lebbé and
  • Nicolas Dumaz

The network defined by phosphatidylinositol-3-kinase (PI3K), AKT, and mammalian target of rapamycin (mTOR) plays a major role in melanoma oncogenesis and has been implicated in BRAF inhibitor resistance. The central role of RICTOR (rapamycin-insensit...

(This article belongs to the Special Issue Targeted Therapies for Cancer)
  • Article
  • Open Access
3 Citations
2,338 Views
19 Pages

1H and 31P Magnetic Resonance Spectroscopic Metabolomic Imaging: Assessing Mitogen-Activated Protein Kinase Inhibition in Melanoma

  • Pradeep Kumar Gupta,
  • Stepan Orlovskiy,
  • Fernando Arias-Mendoza,
  • David S. Nelson and
  • Kavindra Nath

19 July 2024

The MAPK signaling pathway with BRAF mutations has been shown to drive the pathogenesis of 40–60% of melanomas. Inhibitors of this pathway’s BRAF and MEK components are currently used to treat these malignancies. However, responses to the...

(This article belongs to the Collection Tumor Microenvironment: Interaction and Metabolism)
  • Article
  • Open Access
14 Citations
4,509 Views
13 Pages

Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models

  • XuSha Zhou,
  • Jing Zhao,
  • Jian V. Zhang,
  • Yinglin Wu and ,
  • Lei Wang,
  • Xiaoqing Chen,
  • Dongmei Ji and
  • Grace Guoying Zhou
  • + 3 authors+ 0 author

3 September 2021

Oncolytic virus (OV) as a promising therapeutic agent can selectively infect and kill tumor cells with naturally inherited or engineered properties. Considering the limitations of OVs monotherapy, combination therapy has been widely explored. MEK inh...

(This article belongs to the Special Issue Oncolytic HSVs)
  • Article
  • Open Access
31 Citations
5,471 Views
19 Pages

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma

  • Hima Patel,
  • Rosalin Mishra,
  • Nour Yacoub,
  • Samar Alanazi and ,
  • Mary Kate Kilroy and
  • Joan T. Garrett
  • + 1 author+ 0 author

22 November 2021

The use of BRAF and MEK inhibitors for patients with BRAF-mutant melanoma is limited as patients relapse on treatment as quickly as 6 months due to acquired resistance. We generated trametinib and dabrafenib resistant melanoma (TDR) cell lines to the...

(This article belongs to the Collection Drug Resistance and Novel Therapies in Cancers)
  • Article
  • Open Access
24 Citations
5,232 Views
23 Pages

P38 MAPK Promotes Migration and Metastatic Activity of BRAF Mutant Melanoma Cells by Inducing Degradation of PMCA4b

  • Randa Naffa,
  • Lisa Vogel,
  • Luca Hegedűs,
  • Katalin Pászty and ,
  • Sarolta Tóth,
  • Kornélia Kelemen,
  • Neha Singh,
  • Attila Reményi,
  • Enikő Kállay and
  • Ágnes Enyedi
  • + 8 authors+ 3 authors

13 May 2020

Metastatic melanoma is the most aggressive type of skin cancer. Previously, we identified the plasma membrane Ca2+ pump isoform 4b (PMCA4b or ATP2B4) as a putative metastasis suppressor in BRAF mutant melanoma cells. Metastasis suppressors are often...

(This article belongs to the Section Cell Signaling)
  • Review
  • Open Access
39 Citations
14,145 Views
25 Pages

Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers

  • Khine S. Shan,
  • Tauseef U. Rehman,
  • Stan Ivanov,
  • Gelenis Domingo and
  • Luis E. Raez

The mitogen-activated protein kinase (MAPK) pathway is essential for cellular proliferation, growth, and survival. Constitutive activation of this pathway by BRAF mutations can cause downstream activation of kinases, leading to uncontrolled cellular...

(This article belongs to the Special Issue From Basic Science to Treatment Strategies: Personalized Cancer Therapy)
  • Review
  • Open Access
26 Citations
6,805 Views
16 Pages

13 September 2021

The advent of mitogen-activated protein kinase (MAPK) inhibitors that directly inhibit tumor growth and of immune checkpoint inhibitors (ICI) that boost effector T cell responses have strongly improved the treatment of metastatic melanoma. In about h...

(This article belongs to the Special Issue Immune Responses in Cancer Immunology and Immunotherapy)
  • Review
  • Open Access
10 Citations
2,963 Views
12 Pages

30 September 2023

BRAF-targeted therapies are widely used for the treatment of melanoma patients with BRAF V600 mutations. Vemurafenib, dabrafenib as well as encorafenib have demonstrated substantial therapeutic activity; however, as is the case with other chemotherap...

(This article belongs to the Special Issue Cellular Senescence in Physiological and Pathological Processes 2.0)

of 6